RENÉE AGUIAR LUCANDER

Chief Executive Officer

C-suiteF

FI·FIN-FSA

Hansa Biopharma AB Hansa Biopharma AB

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Explore the detailed record of transactions filed by RENÉE AGUIAR LUCANDER, Chief Executive Officer. Insider active across 2 companies, notably Hansa Biopharma AB. Aggregated, 2 reports have been logged. The latest transaction was disclosed on 28 July 2025 — Purchase. Regulator: FIN-FSA. The full history is openly available.

Declarations2 total

Executives●PurchaseHHansa Biopharma AB39FIN-FSA

R

RENÉE AGUIAR LUCANDERVerkställande direktör (VD)

€2m1,652,500 shares@ €0.9740.056% mcap92.9% of flow

Teckningsoption

FI:A003R120-1·27 Jul 2025

Ideal exit: 23 Apr 2026 (T+270)

FIN-FSA ↗

Executives●PurchaseHHansa Biopharma AB27FIN-FSA

R

RENÉE AGUIAR LUCANDERVerkställande direktör (VD)

€122,93450,000 shares@ €2.45870.0043% mcap7.1% of flow

Aktie

FI:A003R122-1·28 Jul 2025

Ideal exit: 24 Apr 2026 (T+270)

FIN-FSA ↗

2 of 2 declarations

About RENÉE AGUIAR LUCANDER

RENÉE AGUIAR LUCANDER is the CEO of Hansa Biopharma AB. She is responsible for managing the company and executing its strategy in the biopharmaceutical sector.